share_log

Kymera Therapeutics Receives FDA Orphan Drug Designation For KT-333, A First-in-Class, Investigational STAT3 Degrader For The Treatment Of Cutaneous T-Cell Lymphoma

Kymera Therapeutics Receives FDA Orphan Drug Designation For KT-333, A First-in-Class, Investigational STAT3 Degrader For The Treatment Of Cutaneous T-Cell Lymphoma

Kymera治疗公司获得FDA的KT-333孤儿药物称号，KT-333是治疗皮肤T细胞淋巴瘤的一流研究用STAT3降解剂
Benzinga Real-time News ·  2022/09/15 07:32

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).

凯美拉治疗公司(纳斯达克：KYMR)是一家临床阶段推进蛋白质定向降解以提供新型小分子蛋白质降解剂药物的生物制药公司，该公司今天宣布，美国食品和药物管理局已授予KT-333治疗皮肤T细胞淋巴瘤的孤儿药物称号。

KT-333 is a first-in-class degrader of the transcriptional regulator STAT3. Deregulation of STAT3 signaling has been implicated in the pathogenesis of a variety of cancers, including CTCL. There are currently no approved therapies for CTCL that target this pathway. KT-333 received orphan drug designation for the treatment of Peripheral T-cell Lymphoma (PTCL) earlier this year.

KT-333是转录调控基因STAT3的一种一流降解剂。STAT3信号的失控与包括CTCL在内的多种癌症的发病机制有关。目前还没有针对这一途径的CTCL已获批准的治疗方法。今年早些时候，KT-333获得了治疗外周T细胞淋巴瘤(PTCL)的孤儿药物指定。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发